ClinicalTrials.gg
CompletedNCT05767346MAPLE-HCMUpdated Jun 9, 2026Results posted

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

A Phase 3 interventional study of Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) and Placebo to match aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics. Completed at 71 sites in 13 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Enrollment
4th of 11
175 · median 96
Started
2023
with 2 others
Phase 3
5 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
7 of 11
Cytokinetics

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 6th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

  • Obstructive Hypertrophic Cardiomyopathy
  • Aficamten
  • Metoprolol
  • oHCM
  • CK-3773274
  • CK-274
  • MAPLE-HCM
  • MAPLE
  • CY 6032
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who meet all the following criteria at screening may be included in the trial:

    • Males and females between 18 to 85 years of age, inclusive, at screening
    • \< 35 kg/m2
    • Diagnosed with oHCM per the following criteria by cardiac magnetic resonance imaging (CMR) or echocardiography -

      • Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease and
      • Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory:

        1. ≥ 15 mm in one or more myocardial segments OR
        2. ≥ 13 mm in one or more wall segments and a known disease-causing gene mutation or positive family history of HCM
    • (NYHA) class II or III
    • Has a Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) score of ≤ 90 at screening
    • Has a screening echocardiogram with the following determined by the echocardiography core laboratory:

      • Resting left ventricular outflow tract gradient (LVOT-G) > 30 mm Hg and/or post-Valsalva LVOT-G ≥ 50 mmHg at screening AND
      • ≥ 60%
    • ≥ 10g/dL
    • Respiratory exchange ratio (RER) ≥ 1.05 and peak oxygen uptake (pVO2) \< 100% predicted on the screening cardiopulmonary exercise testing (CPET) per the core laboratory
    • Patients previously exposed to mavacamten are allowed to participate but must be off mavacamten for at least 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Any of the following criteria will exclude potential participants from the trial:

    • Medical indication for either beta blocker or calcium-channel blockers prohibiting drug discontinuation other than oHCM
    • History of intolerance or medical to beta blocker therapy
    • Resting Systolic Blood Pressure (SBP) of > 160 mmHg
    • Resting heart rate of > 100 bpm
    • Significant valvular heart disease

      1. Moderate-severe valvular aortic stenosis or fixed subaortic obstruction
      2. Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator judgment)
    • Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis)
    • History of LV systolic dysfunction ( \< 45%) or stress cardiomyopathy at any time during their clinical course
    • Inability to exercise on a treadmill or bicycle (eg, orthopedic limitations)
    • Documented room air oxygen saturation reading \< 90% at screening
    • Planned septal reduction treatment that cannot be deferred during the trial period
    • History of septal reduction therapy (surgical myectomy or alcohol septal ablation) within 6 months of screening
    • History of paroxysmal or persistent atrial fibrillation or atrial flutter. Atrial flutter treated with radio frequency ablation without recurrence within the last 6 months prior to screening is allowed.
    • Current or recent (\< 4 weeks) therapy with disopyramide
    • History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening
    • Has received prior treatment with aficamten or previously intolerant (reduced LVEF requiring permanent drug discontinuation) to mavacamten
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Aficamten up to 20 mg plus placebo for metoprolol

    Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.

    Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) · Drug: Placebo to match metoprolol succinate

  • Active comparator
    Metoprolol succinate up to 200 mg plus placebo for aficamten

    Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.

    Drug: Placebo to match aficamten · Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)

Interventions

  • DrugAficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)

    Drug page: Aficamten

    Aficamten (CK-3773274) tablets administered orally

  • DrugPlacebo to match aficamten

    Placebo for aficamten (CK-3773274) administered orally

  • DrugMetoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)

    Drug page: Metoprolol

    Metoprolol succinate tablets administered orally

  • DrugPlacebo to match metoprolol succinate

    Placebo for metoprolol succinate administered orally

06

What researchers measure

Primary outcomes

  1. Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)

    Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Exercise capacity was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class

    Effect of aficamten compared with metoprolol succinate on NYHA Functional Classification

    Time frame: Baseline to Week 24

  2. Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)

    Effect of aficamten compared with metoprolol succinate on participant health status was measured by change in KCCQ-CSS. The KCCQ is a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, quality of life, and social limitation of patients with heart failure symptoms. The CSS is the sum of the physical limitation score and the total symptom score. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

    Time frame: Baseline to Week 24

  3. Change in Left Ventricular Mass Index (LVMI)

    Effect of aficamten on mass of the heart as compared with metoprolol succinate

    Time frame: Baseline to Week 24

  4. Change in Left Atrial Volume Index (LAVI)

    Effect of aficamten on size of the heart as compared with metoprolol succinate

    Time frame: Baseline to Week 24

  5. Change From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

    Effect of aficamten on NT-proBNP as compared with metoprolol succinate. For change in NT-proBNP from baseline to Week 24, the log transformed proportional change up to Week 24 was analyzed using a mixed model for repeated measures (MMRM) then the estimate was back transformed to obtain the ratio.

    Time frame: Baseline to Week 24

  6. Change in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)

    Effect of aficamten on post-Valsalva LVOT-G as compared with metoprolol succinate

    Time frame: Baseline to Week 24

07

Results

Posted Jun 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneAficamtenMetoprolol
Started8887
Completed treatment8784
Completed8786
Not completed11
Withdrew: Death10
Withdrew: Adverse event01

Outcome measures

PrimaryChange in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)

Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Exercise capacity was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.

Time frame:
Baseline to Week 24
Reported as:
Mean · mL/kg/min
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
mL/kg/minAficamtenMetoprolol
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)1.07 ± 2.767-1.24 ± 2.186
Statistical analysis
  • Aficamten vs Metoprolol · ANCOVA · p = <0.0001 · Least squares mean difference: 2.30 · 95% CI 1.52 to 3.07
SecondaryProportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class

Effect of aficamten compared with metoprolol succinate on NYHA Functional Classification

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Proportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class
ParticipantsAficamtenMetoprolol
Proportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class4523
Statistical analysis
  • Aficamten · Common rate difference: 24.8 · 95% CI 10.9 to 38.7Common Rate Difference Aficamten vs Metoprolol
SecondaryChange in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)

Effect of aficamten compared with metoprolol succinate on participant health status was measured by change in KCCQ-CSS. The KCCQ is a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, quality of life, and social limitation of patients with heart failure symptoms. The CSS is the sum of the physical limitation score and the total symptom score. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · points on a scale
Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
points on a scaleAficamtenMetoprolol
Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)15.3 ± 1.568.3 ± 1.57
Statistical analysis
  • Aficamten · Mixed Models Analysis · p = 0.002 · Least squares mean difference: 6.9 · 95% CI 2.6 to 11.3
SecondaryChange in Left Ventricular Mass Index (LVMI)

Effect of aficamten on mass of the heart as compared with metoprolol succinate

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · g/m^2
Change in Left Ventricular Mass Index (LVMI)
g/m^2AficamtenMetoprolol
Change in Left Ventricular Mass Index (LVMI)-9.19 ± 2.492-4.34 ± 2.486
Statistical analysis
  • Aficamten vs Metoprolol · Mixed Models Analysis · p = 0.163 · Least squares mean difference: -4.86 · 95% CI -11.70 to 1.98
SecondaryChange in Left Atrial Volume Index (LAVI)

Effect of aficamten on size of the heart as compared with metoprolol succinate

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mL/m^2
Change in Left Atrial Volume Index (LAVI)
mL/m^2AficamtenMetoprolol
Change in Left Atrial Volume Index (LAVI)-3.87 ± 0.7853.12 ± 0.789
Statistical analysis
  • Aficamten vs Metoprolol · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: -6.99 · 95% CI -9.14 to -4.85
SecondaryChange From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

Effect of aficamten on NT-proBNP as compared with metoprolol succinate. For change in NT-proBNP from baseline to Week 24, the log transformed proportional change up to Week 24 was analyzed using a mixed model for repeated measures (MMRM) then the estimate was back transformed to obtain the ratio.

Time frame:
Baseline to Week 24
Reported as:
Geometric least squares mean · ratio
Change From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
ratioAficamtenMetoprolol
Change From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)0.26 (0.23 to 0.31)1.38 (1.18 to 1.61)
Statistical analysis
  • Aficamten vs Metoprolol · Mixed Models Analysis · p = < 0.0001
  • Aficamten vs Metoprolol · Mixed Models Analysis · p = <0.0001 · Geometric least squares mean ratio: 0.19 · 95% CI 0.15 to 0.24
SecondaryChange in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)

Effect of aficamten on post-Valsalva LVOT-G as compared with metoprolol succinate

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mmHg
Change in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)
mmHgAficamtenMetoprolol
Change in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)-40.34 ± 3.098-5.44 ± 3.100
Statistical analysis
  • Aficamten vs Metoprolol · Mixed Models Analysis · p = < 0.0001 · Least squares mean difference: -34.90 · 95% CI -43.39 to -26.41

Adverse events

Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aficamten1/88 (1.1%)7/88 (8%)46/88 (52.3%)
Metoprolol0/87 (0%)6/87 (6.9%)43/87 (49.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAficamtenMetoprolol
Atrial fibrillationCardiac disorders2/881/87
Acute left ventricular failureCardiac disorders0/881/87
Blood loss anaemiaBlood and lymphatic system disorders1/881/87
Abdominal wall hematomaGastrointestinal disorders0/881/87
Non-cardiac chest painGeneral disorders0/881/87
Ischemic strokeNervous system disorders0/881/87
SyncopeNervous system disorders0/881/87
HematomaVascular disorders0/881/87
HypertensionVascular disorders0/881/87
HypotensionVascular disorders0/881/87
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAficamtenMetoprolol
DizzinessNervous system disorders6/8815/87
Upper respiratory tract infectionInfections and infestations12/8810/87
FatigueGeneral disorders5/889/87
HypertensionVascular disorders9/882/87
PalpitationsCardiac disorders3/888/87
Angina pectorisCardiac disorders8/884/87
COVID-19Infections and infestations7/884/87
DyspnoeaRespiratory, thoracic and mediastinal disorders7/886/87
HeadacheNervous system disorders6/886/87
NasopharyngitisInfections and infestations1/886/87

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AficamtenMetoprololTotal
Mean58.9 ± 13.3356.5 ± 13.0657.7 ± 13.21
Sex: Female, Male
Sex: Female, Male(Participants)AficamtenMetoprololTotal
Female363773
Male5250102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AficamtenMetoprololTotal
Hispanic or Latino111122
Not Hispanic or Latino7373146
Unknown or Not Reported437
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AficamtenMetoprololTotal
Race — White7070140
Race — Black or African American101
Race — Native Hawaiian or Other Pacific Islander000
Race — American Indian or Alaska Native000
Race — Other112
Race — Not Reported145
Race — Unknown202
Race — Asian131225
Region of Enrollment
Region of Enrollment(Participants)AficamtenMetoprololTotal
Brazil011
Canada202
China111122
Denmark415
France224
Germany101
Hungary5611
Israel033
Italy404
Netherlands134
Spain121628
United Kingdom358
United States433982
Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(mL/kg/min)AficamtenMetoprololTotal
Mean19.52 ± 4.78620.19 ± 5.31319.86 ± 5.052
Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)(Points on a Scale)AficamtenMetoprololTotal
Mean65.5 ± 17.0166.0 ± 5.9965.8 ± 16.47
08

Study locations

71 sites
  • Alaska Heart and Vascular Institute
    Anchorage, Alaska 99508, United States
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • UC San Diego Health - Sulpizio Cardiovascular Center
    La Jolla, California 92037, United States
  • Cedars-Sinai Medical Center (Smidt Heart Institute)
    Los Angeles, California 90048, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06519, United States
  • AdventHealth
    Orlando, Florida 32804, United States
  • Emory Clinic
    Atlanta, Georgia 30322, United States
  • Piedmont Fayette Hospital
    Fayetteville, Georgia 30214, United States
  • Northwestern University
    Evanston, Illinois 60208, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Lahey Hospital & Medical Center
    Burlington, Massachusetts 01803, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Columbia University Medical Center/New York Presbyterian Hospital
    New York, New York 10032, United States
  • Sanger Heart & Vascular Institute - HCM Clinic
    Charlotte, North Carolina 28204, United States
  • Duke Health Center Arringdon
    Morrisville, North Carolina 27560, United States
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Division of Heart Failure and Transplantation (Hospital of the University of Pennsylvania)
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Ascension Saint Thomas Heart West
    Nashville, Tennessee 37205, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • CHI St. Luke's Health Baylor-St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • Inova Schar Heart and Vascular
    Falls Church, Virginia 22042, United States
  • Instituto de Pesquisa Clinica de Campinas - IPECC
    Campinas, São Paulo 13060-080, Brazil
  • lnstituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
    São Paulo, São Paulo 05403-900, Brazil
  • Institutdo Danta Pazzanese
    Ibirapuera, 04012-909, Brazil
  • Institut universitaire de cardiologie et de pneumonlogie de Quebec - Universite Laval
    Québec, Canada
  • Xiangya Second Hospital of Central South University
    Changsha, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, 510080, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Zhongshan Hospital Fudan University
    Shanghai, China
  • Renmin Hospital of Wuhan University
    Wuhan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
  • Aarhus University Hospital
    Aarhus, Denmark
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • CHU La Timone
    Marseille, France
  • Hopital Europeen Georges Pompidou
    Paris, France
  • Hopital Lariboisiere - APHP
    Paris, France
  • Hopital Cardiologique Haut Leveque - CHU de Bordeaux
    Pessac, France
  • CHU Pontchaillou
    Rennes, France
  • Hopital Laennec - CHU de Nantes
    Saint-Herblain, France
  • Charite-Universitatsmedizin Berlin - Campus Virchow Klinikum
    Berlin, Germany
  • Universitaetsklinikum Essen
    Essen, Germany
  • Universitaetsklinikum Jena
    Jena, Germany
  • Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika
    Budapest, Hungary
  • Barzilai Medical Center
    Ashkelon, Israel
  • Hadassah Hebrew Medical Center- Ein Kerem
    Jerusalem, Israel
  • The Chaim Sheba Medical Center
    Ramat Gan, Israel
  • Kaplan Medical Center
    Rehovot, Israel
  • Ziv Medical Center
    Safed, Israel
  • AOU Careggi
    Florence, Italy
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Complejo Hospitalario Universitario A Coruna
    A Coruña, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Clinico Universitario Virgen Arrixaca
    El Palmar, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
  • Hospital Universitario Son Llatzer
    Son Ferriol, Spain
  • NHS Greater Glasgow and Clyde
    Glasgow, United Kingdom
  • Liverpool Heart and Chest Hospital NHS Foundation Trust
    Liverpool, United Kingdom
  • Barts Health NHS Trust
    London, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
  • St George's University Hospitals NHS Foundation Trust
    London, United Kingdom
  • Oxford University Hospital NHS Trust - John Radcliffe Hospital - OCMR
    Oxford, United Kingdom
09

References and documents

Publications

  • Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Pena-Pena ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM; MAPLE-HCM Investigators. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 17:e261730. doi: 10.1001/jamacardio.2026.1730. Online ahead of print. PubMed 42307914 ↗
  • Nassif ME, Garcia-Pavia P, Masri A, Merkely B, Pena-Pena ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Lewis GD, Mann A, Maron MS, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Spertus JA; MAPLE-HCM Investigators. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2026 Mar 3;87(8):1046-1058. doi: 10.1016/j.jacc.2025.10.059. Epub 2025 Nov 18. PubMed 41493295 ↗
  • Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Pena-Pena ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro A, Elliott P, Hegde SM, Kulac IJ, Lakdawala NK, Lewis GD, Mann A, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Maron MS; MAPLE-HCM Investigators. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. J Am Coll Cardiol. 2026 Mar 3;87(8):1029-1042. doi: 10.1016/j.jacc.2025.10.057. Epub 2025 Nov 18. PubMed 41348072 ↗
  • Hegde SM, Wang X, Garcia-Pavia P, Getchevski S, Masri A, Merkely B, Nassif ME, Pena-Pena ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Lakdawala NK, Mann A, Maron MS, Nair A, Poulsen SH, Reant P, Schulze PC, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Solomon SD; MAPLE-HCM Investigators. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. 2025 Dec 16;86(24):2452-2467. doi: 10.1016/j.jacc.2025.08.022. Epub 2025 Aug 27. PubMed 40932433 ↗
  • Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pena-Pena ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA; MAPLE-HCM Investigators. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):949-960. doi: 10.1056/NEJMoa2504654. Epub 2025 Aug 30. PubMed 40888697 ↗
  • Garcia-Pavia P, Bilen O, Burroughs M, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Mann A, Nair A, Nassif ME, Poulsen SH, Reant P, Schulze PC, Wang A, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Fifer MA; MAPLE-HCM Study Investigators. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Fail. 2025 Feb;13(2):346-357. doi: 10.1016/j.jchf.2024.11.011. PubMed 39909646 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Feb 2025, 20 months.

Results were first posted in Jun 2026, 1 year 3 months after primary completion.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
Mar 14, 2023
StartActual
Jun 20, 2023
Primary completionActual
Feb 28, 2025
CompletionActual
Mar 28, 2025
Results first posted
Jun 9, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05767346
Lead sponsor
Cytokinetics
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Jun 20, 2023
Primary completion
Feb 28, 2025
Completion
Mar 28, 2025
Results posted
Jun 9, 2026
Last update
Jun 9, 2026

Study contacts

Scientific Leadership
study director · Cytokinetics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion